Drug intelligence / Profile preview

GENLITE PLUS

Development stage: Unknown
Lead developer: Wonne International
Modality: Small Molecules
Administration: Ophthalmic

Overview

GENLITE PLUS is an ophthalmic solution marketed by Wonne International, an Indian pharmaceutical company. The formulation contains the inorganic salts potassium iodide and calcium chloride. It is primarily used for the management of lenticular opacities and the prevention of early-stage cataract progression. Potassium iodide is traditionally believed to facilitate the resorption of lens opacities and act as an antioxidant, while calcium chloride provides essential electrolytes to support lens metabolism. The product is commercially available as a finished pharmaceutical formulation in the Indian market.

Brand names: GENLITE PLUS
Other names: GENLITE PLUS Eye Droppotassium iodide + calcium chloride

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on GENLITE PLUS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GENLITE PLUS.

Explore the full profile